

Financial Tear Sheet

Corporate Profile

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

Stock Information

XBIT (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$4.12
Change (%)	▼ 0.05 (1.20%)
Volume	80,445
52 Week Low	\$2.77
Market Cap	\$145,929,461
Rolling EPS	-1.47
PE Ratio	0
Shares Outstanding	35,419,772
Data as of 10/20/17 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

Date	Title
10/18/17	XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
10/03/17	XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board
09/21/17	XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
09/15/17	8-K
08/08/17	10-Q
07/11/17	4
07/11/17	3

Primary IR Contact

James S. Whitehurst
XBiotech
Phone: +1 512.386.2993
Email: swhitehurst@xbiotech.com

Management

John Simard	Founder, President, Chief Executive Officer & Chairman
Norma I. Gonzalez	Vice President of Quality
Benjamin Guzman	Senior Vice President of Corporate Strategy & Finance
Queena Han, C.P.A., C.G.A.	Vice President of Finance and Human Resources and Secretary
Sushma Shivaswamy, Ph.D.	Vice President of Research and Development
Michael Stecher, M.D.	Medical Director

Board of Directors

John Simard	Founder, President, Chief Executive Officer & Chairman
Fabrizio Bonanni, Dr. Chem.	Director
Thorpe McKenzie	Director
Daniel Vasella, M.D.	Director